MannKind Co. (NASDAQ:MNKD) VP Stuart A. Tross acquired 39,840 shares of MannKind stock in a transaction on Thursday, December 21st. The shares were purchased at an average price of $2.52 per share, for a total transaction of $100,396.80. Following the completion of the acquisition, the vice president now directly owns 59,840 shares in the company, valued at $150,796.80. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.
MannKind Co. (NASDAQ:MNKD) traded down $0.11 during trading on Friday, hitting $2.41. The stock had a trading volume of 4,828,200 shares, compared to its average volume of 4,005,895. The company has a debt-to-equity ratio of -0.43, a current ratio of 0.31 and a quick ratio of 0.28. The firm has a market cap of $271.02, a PE ratio of -8.93 and a beta of 3.07. MannKind Co. has a 52-week low of $0.67 and a 52-week high of $6.96.
MannKind (NASDAQ:MNKD) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.11). The business had revenue of $2.04 million during the quarter, compared to analyst estimates of $2.56 million. MannKind had a negative return on equity of 24.93% and a negative net margin of 155.83%. The firm’s revenue for the quarter was down 98.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.30 EPS. equities research analysts forecast that MannKind Co. will post -1.13 EPS for the current year.
Several brokerages have issued reports on MNKD. BidaskClub cut MannKind from a “hold” rating to a “sell” rating in a research report on Friday. Zacks Investment Research cut MannKind from a “hold” rating to a “sell” rating in a research report on Wednesday, December 13th. ValuEngine raised MannKind from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 30th. HC Wainwright reaffirmed a “buy” rating on shares of MannKind in a research report on Wednesday, November 8th. Finally, Maxim Group reaffirmed a “hold” rating on shares of MannKind in a research report on Wednesday, November 1st. Five analysts have rated the stock with a sell rating, one has given a hold rating and one has issued a buy rating to the stock. The company has an average rating of “Sell” and an average price target of $0.92.
MannKind Company Profile
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.